Minimizing drug wastage (DW) and cost of cabazitaxel used to treat metastatic castrate-resistant prostate cancer (mCRPC).

被引：0
|
作者：
Jiang, Di Maria
Fallah-Rad, Nazanin
Lee, Roy
Ng, Pamela
Smith, Alan D.
Hansen, Aaron Richard
Joshua, Anthony M.
Sridhar, Srikala S.
机构：
[1] Univ Hlth Network, Princess Margaret Canc Ctr, Toronto, ON, Canada
[2] Princess Margaret Canc Ctr, Toronto, ON, Canada
[3] Univ Toronto, Princess Margaret Canc Ctr, Toronto, ON, Canada
[4] Princess Margaret Hosp, Toronto, ON, Canada
[5] Univ Toronto, Univ Hlth Network, Princess Margaret Canc Ctr, Toronto, ON, Canada
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 15期
关键词：
D O I：
10.1200/JCO.2019.37.15_suppl.6550
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
6550
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Cabazitaxel in metastatic castrate resistant prostate cancer (mCRPC) in the era of enzalutamide (ENZA) and abiraterone acetate (AA).
    Body, Amy
    Pranavan, Gane
    Malik, Laeeq
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [22] Genomic landscape of CDK12 mutated metastatic castrate-resistant prostate cancer (mCRPC).
    Grivas, Petros
    Bratslavsky, Gennady
    Jacob, Joseph M.
    Necchi, Andrea
    Spiess, Philippe E.
    Danziger, Natalie
    Huang, Richard
    Mata, Douglas A.
    Decker, Brennan James
    Sokol, Ethan
    Montesion, Meagan
    Tukachinsky, Hanna
    Venstrom, Jeffrey Michael
    Ross, Jeffrey S.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
  • [23] Metformin (Met): A cost-effective adjunct therapy with enzalutamide (Enza) for metastatic castrate-resistant prostate cancer (mCRPC)?
    Hill, Jordan
    Paulden, Mike
    McCabe, Christopher
    Venner, Peter
    Danielson, Brita Lavender
    North, Scott A.
    Usmani, Nawaid
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (02)
  • [24] Does Pretreatment with Abiraterone Acetate (AA) Or Enzlutamide (ENZA) Affect the Efficacy of Subsequent Cabazitaxel Chemotherapy in Metastatic Castrate-Resistant Prostate Cancer (mCRPC)?
    Body, A.
    Pranavan, G.
    Malik, L.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2017, 13 : 56 - 56
  • [25] Abiraterone for the Treatment of Metastatic Castrate-Resistant Prostate Cancer
    Beckett, Robert D.
    Rodeffer, Kathryn M.
    Snodgrass, Rachel
    ANNALS OF PHARMACOTHERAPY, 2012, 46 (7-8) : 1016 - 1024
  • [26] Treatment sequencing in metastatic castrate-resistant prostate cancer
    Sartor, Oliver
    Gillessen, Silke
    ASIAN JOURNAL OF ANDROLOGY, 2014, 16 (03) : 426 - 431
  • [27] Novel Therapies for Metastatic Castrate-Resistant Prostate Cancer
    Dayyani, Farshid
    Gallick, Gary E.
    Logothetis, Christopher J.
    Corn, Paul G.
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2011, 103 (22): : 1665 - 1675
  • [28] Metastatic Castrate-Resistant Prostate Cancer Practical Review
    Moeller, Abby
    Cookson, Michael
    Patel, Sanjay G.
    PHYSICIAN ASSISTANT CLINICS, 2018, 3 (01) : 11 - +
  • [29] Real life treatment sequences and survival of men with metastatic castrate-resistant prostate cancer (mCRPC) receiving cabazitaxel in clinical practice across England.
    Birtle, Alison J.
    Bahl, Amit
    Butt, Mohammad
    Pan, Shermaine
    Carter, Angela M.
    Thomson, Alastair H.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (06)
  • [30] Phase 2 study (AARDVARC) of AZD4635 in combination with durvalumab and cabazitaxel in patients (pts) with progressive metastatic castrate-resistant prostate cancer (mCRPC).
    Gordoa, Teresa Alonso
    Goodman, Michael Moses
    Vulsteke, Christof
    Roubaud, Guilhem
    Zhang, Jingsong
    Parikh, Mamta
    Piulats, Josep M.
    Azaro, Analia
    James, Gareth D.
    Cavazzina, Riccardo
    Gangl, Eric
    Thompson, Jeff
    Pouliot, Gayle Pageau
    Kumar, Rakesh
    Sweeney, Christopher
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
12345